Dynamical modeling of proliferative-invasive plasticity and IFNγ signaling in melanoma reveals mechanisms of PD-L1 expression heterogeneity

Single-cell transcriptomics of NRAS-mutated melanoma transitioning to drug resistance reveals P2RX7 as an indicator of early drug response

(2023) Tijana Randic et al.   Cell Reports

Targeting SOX10-deficient cells to reduce the dormant-invasive phenotype state in melanoma

(2022) Claudia Capparelli et al.   Nature Communications

Adaptive translational reprogramming of metabolism limits the response to targeted therapy in BRAFV600 melanoma

(2022) Lorey K. Smith et al.   Nature Communications

ZEB1 transcription factor promotes immune escape in melanoma

(2022) Maud Plaschka et al.   Journal for ImmunoTherapy of Cancer

A cellular hierarchy in melanoma uncouples growth and metastasis

(2022) Panagiotis Karras et al.   NATURE

Innate immune checkpoint inhibitor resistance is associated with melanoma sub-types exhibiting invasive and de-differentiated gene expression signatures

(2022) Sultana Mehbuba Hossain et al.   Frontiers in Immunology

Quantitative landscapes reveal trajectories of cell-state transitions associated with drug resistance in melanoma

(2022) Maalavika Pillai et al.   iScience

Regulation of PD-L1 expression in the tumor microenvironment

(2021) Ming Yi et al.   Journal of Hematology & Oncology

Variability within rare cell states enables multiple paths toward drug resistance

(2021) Benjamin L. Emert et al.   NATURE BIOTECHNOLOGY

Adaptive Therapy for Metastatic Melanoma: Predictions from Patient Calibrated Mathematical Models

(2021) Eunjung Kim et al.   Cancers

Melanoma differentiation trajectories determine sensitivity towards pre-existing CD8+ tumor-infiltrating lymphocytes

(2021) Franziska Noelle Harbers et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

Transcriptional Reprogramming and Constitutive PD-L1 Expression in Melanoma Are Associated with Dedifferentiation and Activation of Interferon and Tumour Necrosis Factor Signalling Pathways

(2021) Antonio Ahn et al.   Cancers

PD-L1 Overexpression, SWI/SNF Complex Deregulation, and Profound Transcriptomic Changes Characterize Cancer-Dependent Exhaustion of Persistently Activated CD4+ T Cells

(2021) Iga Jancewicz et al.   Cancers

Melanoma Plasticity: Promoter of Metastasis and Resistance to Therapy

(2021) Fan Huang et al.   Frontiers in Oncology

SOX10 Regulates Melanoma Immunogenicity through an IRF4–IRF1 Axis

(2021) Satoru Yokoyama et al.   CANCER RESEARCH

Treatment of Advanced Melanoma in 2020 and Beyond

(2020) Russell W. Jenkins et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

PD‑L1 expression increased by IFN‑γ via JAK2‑STAT1 signaling and predicts a poor survival in colorectal cancer

(2020) Tiancheng Zhao et al.   Oncology Letters

Robust gene expression programs underlie recurrent cell states and phenotype switching in melanoma

(2020) Jasper Wouters et al.   NATURE CELL BIOLOGY

Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma

(2020) Catherine S. Grasso et al.   CANCER CELL

Recapitulation of Neural Crest Specification and EMT via Induction from Neural Plate Border-like Cells

(2020) Gerson Shigeru Kobayashi et al.   Stem Cell Reports

Tumor Microenvironment: Implications in Melanoma Resistance to Targeted Therapy and Immunotherapy

(2020) Italia Falcone et al.   Cancers

The Role of Intratumor Heterogeneity in the Response of Metastatic Non-Small Cell Lung Cancer to Immune Checkpoint Inhibitors

(2020) Marcin Nicoś et al.   Frontiers in Oncology

Computational Modeling of the Crosstalk Between Macrophage Polarization and Tumor Cell Plasticity in the Tumor Microenvironment

(2019) Xuefei Li et al.   Frontiers in Oncology

SA-49, a novel aloperine derivative, induces MITF-dependent lysosomal degradation of PD-L1

(2019) Na Zhang et al.   EBioMedicine

Many ways to resistance: How melanoma cells evade targeted therapies

(2019) Ines Kozar et al.   BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER

Next-generation characterization of the Cancer Cell Line Encyclopedia

(2019) Mahmoud Ghandi et al.   NATURE

Benchmark and integration of resources for the estimation of human transcription factor activities

(2019) Luz Garcia-Alonso et al.   GENOME RESEARCH

IRF1 Inhibits Antitumor Immunity through the Upregulation of PD-L1 in the Tumor Cell

(2019) Lulu Shao et al.   Cancer Immunology Research

PD-L1 regulation by SDH5 via β-catenin/ZEB1 signaling

(2019) Zhan Tuo et al.   OncoImmunology

Multi-stage Differentiation Defines Melanoma Subtypes with Differential Vulnerability to Drug-Induced Iron-Dependent Oxidative Stress

(2018) Jennifer Tsoi et al.   CANCER CELL

Recovering Gene Interactions from Single-Cell Data Using Data Diffusion

(2018) David van Dijk et al.   CELL

Toward Minimal Residual Disease-Directed Therapy in Melanoma

(2018) Florian Rambow et al.   CELL

Single-cell RNA-seq analysis identifies markers of resistance to targeted BRAF inhibitors in melanoma cell populations

(2018) Yu-Jui Ho et al.   GENOME RESEARCH

A Cancer Cell Program Promotes T Cell Exclusion and Resistance to Checkpoint Blockade

(2018) Livnat Jerby-Arnon et al.   CELL

PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity

(2017) Vikram R. Juneja et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Rare cell variability and drug-induced reprogramming as a mode of cancer drug resistance

(2017) Sydney M. Shaffer et al.   NATURE

SCENIC: single-cell regulatory network inference and clustering

(2017) Sara Aibar et al.   NATURE METHODS

Microenvironment-derived factors driving metastatic plasticity in melanoma

(2017) Isabella S. Kim et al.   Nature Communications

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

(2017) Angel Garcia-Diaz et al.   Cell Reports

Interrogating the topological robustness of gene regulatory circuits by randomization

(2017) Bin Huang et al.   PLoS Computational Biology

ZEB1 Regulates Multiple Oncogenic Components Involved in Uveal Melanoma Progression

(2017) Yao Chen et al.   Scientific Reports

Combination Therapies for Melanoma: A New Standard of Care?

(2016) Keiran S. M. Smalley et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Regulation of PD-L1: a novel role of pro-survival signalling in cancer

(2015) J. Chen et al.   ANNALS OF ONCOLOGY

Decoding the regulatory landscape of melanoma reveals TEADS as regulators of the invasive cell state

(2015) Annelien Verfaillie et al.   Nature Communications

MITF and c-Jun antagonism interconnects melanoma dedifferentiation with pro-inflammatory cytokine responsiveness and myeloid cell recruitment

(2015) Stefanie Riesenberg et al.   Nature Communications

Antagonistic Cross-Regulation between Sox9 and Sox10 Controls an Anti-tumorigenic Program in Melanoma

(2015) Olga Shakhova et al.   PLoS Genetics

Methylation-dependent SOX9 expression mediates invasion in human melanoma cells and is a negative prognostic factor in advanced melanoma

(2015) Phil F Cheng et al.   GENOME BIOLOGY

Inducible but Not Constitutive Expression of PD-L1 in Human Melanoma Cells Is Dependent on Activation of NF-κB

(2015) Kavitha Gowrishankar et al.   PLoS One

PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics

(2014) D. Massi et al.   ANNALS OF ONCOLOGY

Identification of a ZEB2-MITF-ZEB1 transcriptional network that controls melanogenesis and melanoma progression

(2014) G Denecker et al.   CELL DEATH AND DIFFERENTIATION

Effects of MAPK and PI3K Pathways on PD-L1 Expression in Melanoma

(2014) M. Atefi et al.   CLINICAL CANCER RESEARCH

SOX10 Promotes Melanoma Cell Invasion by Regulating Melanoma Inhibitory Activity

(2014) Saskia A. Graf et al.   JOURNAL OF INVESTIGATIVE DERMATOLOGY

PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials

(2014) Jason Madore et al.   Pigment Cell & Melanoma Research

IRF-1 responsiveness to IFN-γ predicts different cancer immune phenotypes

(2013) D Murtas et al.   BRITISH JOURNAL OF CANCER

A far-upstream (−70 kb) enhancer mediates Sox9 auto-regulation in somatic tissues during development and adult regeneration

(2013) Timothy J. Mead et al.   NUCLEIC ACIDS RESEARCH

IFN-γinhibits basal andα-MSH-induced melanogenesis

(2013) Jinyoung Son et al.   Pigment Cell & Melanoma Research

Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells

(2013) S. Spranger et al.   Science Translational Medicine

A Landscape of Driver Mutations in Melanoma

(2012) Eran Hodis et al.   CELL

Melanomas resist T-cell therapy through inflammation-induced reversible dedifferentiation

(2012) Jennifer Landsberg et al.   NATURE

Molecular signatures database (MSigDB) 3.0

(2011) A. Liberzon et al.   BIOINFORMATICS

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Differential LEF1 and TCF4 expression is involved in melanoma cell phenotype switching

(2011) Ossia M. Eichhoff et al.   Pigment Cell & Melanoma Research

Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

(2010) Keith T. Flaherty et al.   NEW ENGLAND JOURNAL OF MEDICINE

B7-H1 is a ubiquitous antiapoptotic receptor on cancer cells

(2008) T. Azuma et al.   BLOOD

In vivo Switching of Human Melanoma Cells between Proliferative and Invasive States

(2008) K. S. Hoek et al.   CANCER RESEARCH